Abstract
Psoriasis is a long-lasting autoimmune disease that is characterized by swollen skin patches. Normally, these skin patches are dark, swollen, itchy and scaly. The single application of the innate TLR7/8 ligand Imiquimod (IMQ) in mice easily induces a dermatitis that closely resembles human psoriasis, critically dependent on the axis of IL-23/IL-17. Artemisia dracunculus prepared as an ointment and has been used topically to mice before imiquimod application. The results of the current study showed that A. dracunculus ointment can significantly reduce psoriasis area and severity index in (A. dracunculus ointment + imiquimod group as compared with both control group and (vehicle ointment + imiquimod) group.
Highlights
Psoriasis is one of the world's most common forms of chronic dermatitis
Psoriasis can start at any age, epidemiological studies suggested that it can most commonly occur for the first time between the ages of 15 and 25.(4) its prevalence estimates vary from 0.5% to 4.6%, with rates varying from country to race
In the A. dracunculus ointment only group (Group II) there was no change in Psoriasis Area and Severity Index (PASI) score during the study
Summary
Psoriasis is one of the world's most common forms of chronic dermatitis. The latest U.S epidemiological study showed a prevalence rate of 2.6 percent of the population, which translated into more than 6 million Americans(1) .Psoriasis is an organ-specific autoimmune disease that is triggered by an activated cellular immune system and is similar to other immunemediated diseases such as Crohn’s disease, rheumatoid arthritis (RA), multiple sclerosis (MS) and juvenile-onset diabetes(2) .Iraqi Journal of Pharmaceutical ScienceBecause of its high prevalence, psoriasis is considered to be one of the costliest dermatological diseases. Psoriasis is one of the world's most common forms of chronic dermatitis. The latest U.S epidemiological study showed a prevalence rate of 2.6 percent of the population, which translated into more than 6 million Americans(1). Because of its high prevalence, psoriasis is considered to be one of the costliest dermatological diseases. Estimates of the costs per patient differ significantly depending on the severity of the disease.(3). Psoriasis can start at any age, epidemiological studies suggested that it can most commonly occur for the first time between the ages of 15 and 25.(4) its prevalence estimates vary from 0.5% to 4.6%, with rates varying from country to race. Psoriasis tends to be more common than in lower latitudes and it is more Caucasians than in other races.(5)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
